Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
Juan W. Valle(Cancer Research UK Manchester Institute), Takuji Okusaka(National Cancer Centre Japan), Junji Furuse(Kanagawa Prefectural Hospital Organization), Harpreet Wasan(Hammersmith Hospital), Nobumasa Mizuno(Aichi Cancer Center), Sandy Beare(King's College London), John Bridgewater(University College London Hospitals NHS Foundation Trust), Mark Jitlal(CRUK Lung Cancer Centre of Excellence)
Cited by 395
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k